18 F] -FAPI-42 PET/CT assessment of Progressive right ventricle fibrosis under pressure overload
© 2023. The Author(s)..
BACKGROUND: Right heart failure (RHF) is a complication of pulmonary hypertension (PH) and increases the mortality independently of the underlying disease. However, the process of RHF development and progression is not fully understood. We aimed to develop effective approaches for early diagnosis and precise evaluation of RHF.
METHODS: Right ventricle (RV) pressure overload was performed via pulmonary artery banding (PAB) surgery in Sprague-Dawley (SD) rats to induce RHF. Echocardiography, right heart catheterization, histological staining, fibroblast activation protein (FAP) immunofluorescence and 18 F-labelled FAP inhibitor-42 ([18 F] -FAPI-42) positron emission tomography/computed tomography (PET/CT) were performed at day 3, week 1, 2, 4 and 8 after PAB. RNA sequencing was performed to explore molecular alterations between PAB and sham group at week 2 and week 4 after PAB respectively.
RESULTS: RV hemodynamic disorders were aggravated, and RV function was declined based on right heart catheterization and echocardiography at week 2, 4 and 8 after PAB. Progressive cardiac hypertrophy, fibrosis and capillary rarefaction could be observed in RV from 2 to 8 weeks after PAB. RNA sequencing indicated 80 upregulated genes and 43 downregulated genes in the RV at both week 2 and week 4 after PAB; Gene Ontology (GO) analysis revealed that fibrosis as the most significant biological process in the RV under pressure overload. Immunofluorescence indicated that FAP was upregulated in the RV from week 2 to week 8 after PAB; and [18 F] -FAPI-42 PET/CT revealed FAPI uptake was significantly higher in RV at week 2 and further increased at week 4 and 8 after PAB.
CONCLUSION: RV function is progressively declined with fibrosis as the most prominent molecular change after pressure overload, and [18 F] -FAPI-42 PET/CT is as sensitive and accurate as histopathology in RV fibrosis evaluation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Respiratory research - 24(2023), 1 vom: 06. Nov., Seite 270 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zeng, Xiaohui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
FAPI-PET/CT |
|---|
| Anmerkungen: |
Date Completed 08.11.2023 Date Revised 10.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12931-023-02565-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364245530 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364245530 | ||
| 003 | DE-627 | ||
| 005 | 20231226095033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-023-02565-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364245530 | ||
| 035 | |a (NLM)37932744 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zeng, Xiaohui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 18 F] -FAPI-42 PET/CT assessment of Progressive right ventricle fibrosis under pressure overload |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2023 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Right heart failure (RHF) is a complication of pulmonary hypertension (PH) and increases the mortality independently of the underlying disease. However, the process of RHF development and progression is not fully understood. We aimed to develop effective approaches for early diagnosis and precise evaluation of RHF | ||
| 520 | |a METHODS: Right ventricle (RV) pressure overload was performed via pulmonary artery banding (PAB) surgery in Sprague-Dawley (SD) rats to induce RHF. Echocardiography, right heart catheterization, histological staining, fibroblast activation protein (FAP) immunofluorescence and 18 F-labelled FAP inhibitor-42 ([18 F] -FAPI-42) positron emission tomography/computed tomography (PET/CT) were performed at day 3, week 1, 2, 4 and 8 after PAB. RNA sequencing was performed to explore molecular alterations between PAB and sham group at week 2 and week 4 after PAB respectively | ||
| 520 | |a RESULTS: RV hemodynamic disorders were aggravated, and RV function was declined based on right heart catheterization and echocardiography at week 2, 4 and 8 after PAB. Progressive cardiac hypertrophy, fibrosis and capillary rarefaction could be observed in RV from 2 to 8 weeks after PAB. RNA sequencing indicated 80 upregulated genes and 43 downregulated genes in the RV at both week 2 and week 4 after PAB; Gene Ontology (GO) analysis revealed that fibrosis as the most significant biological process in the RV under pressure overload. Immunofluorescence indicated that FAP was upregulated in the RV from week 2 to week 8 after PAB; and [18 F] -FAPI-42 PET/CT revealed FAPI uptake was significantly higher in RV at week 2 and further increased at week 4 and 8 after PAB | ||
| 520 | |a CONCLUSION: RV function is progressively declined with fibrosis as the most prominent molecular change after pressure overload, and [18 F] -FAPI-42 PET/CT is as sensitive and accurate as histopathology in RV fibrosis evaluation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FAPI-PET/CT | |
| 650 | 4 | |a Fibroblast activation protein | |
| 650 | 4 | |a Fibrosis | |
| 650 | 4 | |a RNA-sequence | |
| 650 | 4 | |a Right Heart Failure | |
| 700 | 1 | |a Zhao, Ruiyue |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zhixiong |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Zhuoji |e verfasserin |4 aut | |
| 700 | 1 | |a Cen, Chunxian |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Shanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Wanxian |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Yanrong |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Kexin |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Shangwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Wenju |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinlu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d 2000 |g 24(2023), 1 vom: 06. Nov., Seite 270 |w (DE-627)NLM115627553 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:06 |g month:11 |g pages:270 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12931-023-02565-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 1 |b 06 |c 11 |h 270 | ||